Cargando…
Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292147/ https://www.ncbi.nlm.nih.gov/pubmed/37377583 http://dx.doi.org/10.3748/wjg.v29.i21.3328 |
_version_ | 1785062826680778752 |
---|---|
author | Sissingh, Noor J Groen, Jesse V Timmerhuis, Hester C Besselink, Marc G Boekestijn, Bas Bollen, Thomas L Bonsing, Bert A Klok, Frederikus A van Santvoort, Hjalmar C Verdonk, Robert C van Eijck, Casper H J van Hooft, Jeanin E Mieog, Jan Sven D |
author_facet | Sissingh, Noor J Groen, Jesse V Timmerhuis, Hester C Besselink, Marc G Boekestijn, Bas Bollen, Thomas L Bonsing, Bert A Klok, Frederikus A van Santvoort, Hjalmar C Verdonk, Robert C van Eijck, Casper H J van Hooft, Jeanin E Mieog, Jan Sven D |
author_sort | Sissingh, Noor J |
collection | PubMed |
description | BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision making of pancreatologists regarding SVT in acute pancreatitis. METHODS: A total of 139 pancreatologists of the Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group were approached to complete an online survey and case vignette survey. The threshold to assume group agreement was set at 75%. RESULTS: The response rate was 67% (n = 93). Seventy-one pancreatologists (77%) regularly prescribed therapeutic anticoagulation in case of SVT, and 12 pancreatologists (13%) for narrowing of splanchnic vein lumen. The most common reason to treat SVT was to avoid complications (87%). Acute thrombosis was the most important factor to prescribe therapeutic anticoagulation (90%). Portal vein thrombosis was chosen as the most preferred location to initiate therapeutic anticoagulation (76%) and splenic vein thrombosis as the least preferred location (86%). The preferred initial agent was low molecular weight heparin (LMWH; 87%). In the case vignettes, therapeutic anticoagulation was prescribed for acute portal vein thrombosis, with or without suspected infected necrosis (82% and 90%), and thrombus progression (88%). Agreement was lacking regarding the selection and duration of long-term anticoagulation, the indication for thrombophilia testing and upper endoscopy, and about whether risk of bleeding is a major barrier for therapeutic anticoagulation. CONCLUSION: In this national survey, the pancreatologists seemed to agree on the use of therapeutic anticoagulation, using LMWH in the acute phase, for acute portal thrombosis and in the case of thrombus progression, irrespective of the presence of infected necrosis. |
format | Online Article Text |
id | pubmed-10292147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-102921472023-06-27 Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study Sissingh, Noor J Groen, Jesse V Timmerhuis, Hester C Besselink, Marc G Boekestijn, Bas Bollen, Thomas L Bonsing, Bert A Klok, Frederikus A van Santvoort, Hjalmar C Verdonk, Robert C van Eijck, Casper H J van Hooft, Jeanin E Mieog, Jan Sven D World J Gastroenterol Observational Study BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision making of pancreatologists regarding SVT in acute pancreatitis. METHODS: A total of 139 pancreatologists of the Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group were approached to complete an online survey and case vignette survey. The threshold to assume group agreement was set at 75%. RESULTS: The response rate was 67% (n = 93). Seventy-one pancreatologists (77%) regularly prescribed therapeutic anticoagulation in case of SVT, and 12 pancreatologists (13%) for narrowing of splanchnic vein lumen. The most common reason to treat SVT was to avoid complications (87%). Acute thrombosis was the most important factor to prescribe therapeutic anticoagulation (90%). Portal vein thrombosis was chosen as the most preferred location to initiate therapeutic anticoagulation (76%) and splenic vein thrombosis as the least preferred location (86%). The preferred initial agent was low molecular weight heparin (LMWH; 87%). In the case vignettes, therapeutic anticoagulation was prescribed for acute portal vein thrombosis, with or without suspected infected necrosis (82% and 90%), and thrombus progression (88%). Agreement was lacking regarding the selection and duration of long-term anticoagulation, the indication for thrombophilia testing and upper endoscopy, and about whether risk of bleeding is a major barrier for therapeutic anticoagulation. CONCLUSION: In this national survey, the pancreatologists seemed to agree on the use of therapeutic anticoagulation, using LMWH in the acute phase, for acute portal thrombosis and in the case of thrombus progression, irrespective of the presence of infected necrosis. Baishideng Publishing Group Inc 2023-06-07 2023-06-07 /pmc/articles/PMC10292147/ /pubmed/37377583 http://dx.doi.org/10.3748/wjg.v29.i21.3328 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Observational Study Sissingh, Noor J Groen, Jesse V Timmerhuis, Hester C Besselink, Marc G Boekestijn, Bas Bollen, Thomas L Bonsing, Bert A Klok, Frederikus A van Santvoort, Hjalmar C Verdonk, Robert C van Eijck, Casper H J van Hooft, Jeanin E Mieog, Jan Sven D Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title_full | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title_fullStr | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title_full_unstemmed | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title_short | Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study |
title_sort | therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: a national survey and case-vignette study |
topic | Observational Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292147/ https://www.ncbi.nlm.nih.gov/pubmed/37377583 http://dx.doi.org/10.3748/wjg.v29.i21.3328 |
work_keys_str_mv | AT sissinghnoorj therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT groenjessev therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT timmerhuishesterc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT besselinkmarcg therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT boekestijnbas therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT bollenthomasl therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT bonsingberta therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT klokfrederikusa therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT vansantvoorthjalmarc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT verdonkrobertc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT vaneijckcasperhj therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT vanhooftjeanine therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy AT mieogjansvend therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy |